ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. VZ
10. LMT

Go back to ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

Immunogen (IMGN) Tops Q3 EPS by 5c, Revenues Beat; Offers 4Q Revenue Guidance Below Consensus

November 6, 2020 6:39 AM EST

Immunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $18.19 million versus the consensus estimate of $15.36 million.

We have generated significant momentum over the last several months, achieving a number of important milestones across the business, said Mark Enyedy, ImmunoGens President and Chief Executive Officer. Our collaboration with Huadong Medicine accelerates access to mirvetuximab for ovarian cancer patients in Greater China with an ideal partner who brings extensive regional and oncology development and commercialization experience and capabilities. Beyond Greater China, we continue to... More